Trilostane therapy for treatment of spontaneous hyperadrenocorticism in cats: 15 cases (2004-2012).
Medical treatment with trilostane improves clinical signs, causes unclear insulin requirement changes, and variable survival times in cats. To characterize the long-term efficacy of trilostane in treating cats with hyperadrenocorticism (HAC). Fifteen client-owned cats with spontaneous HAC. Multicenter descriptive retrospective study with a search performed on all medical records for cats diagnosed with spontaneous HAC. Clinical signs (13 of 15 cats) and ACTH stimulation testing results (13 of 15) improved with trilostane therapy. Diabetes mellitus was reported in 9/15 cases. Insulin requirements decreased by 36% within 2 months in 6/9 diabetic cats. Median survival time was 617 days for all cats (range 80-1,278 days). Complications included weight loss, urinary tract infections, chronic kidney disease, seizures, and recurrent pancreatitis. Hypocortisolemia was documented in 1 case. Cause of death occurred as a result of nonadrenal or nondiabetic illnesses (renal failure, seizures [caused by hypoglycemia or unknown]), or lymphoma. Trilostane ameliorates clinical signs of HAC in cats, is tolerated well in the long term, and can lead to improved regulation of diabetes.